Valuation: Immutep Limited

Market Cap 75.16M 52.18M 45.65M 42.09M 38.95M 73.92M 4.98B 504M 198M 2.45B 196M 192M 8.47B P/E 2026 *
-1.32x
P/E 2027 * -1.88x
Enterprise Value 10.07M 6.99M 6.12M 5.64M 5.22M 9.9M 667M 67.54M 26.48M 328M 26.24M 25.68M 1.14B EV / Sales 2026 *
0.58x
EV / Sales 2027 * -0.67x
Free-Float
96.98%
Yield 2026 *
-
Yield 2027 * -
1 day-1.92%
1 week-8.93%
Current month-3.77%
1 month+8.51%
3 months+24.39%
6 months-88.28%
Current year-87.71%
1 week 0.05
Extreme 0.051
0.06
1 month 0.04
Extreme 0.044
0.06
Current year 0.03
Extreme 0.028
0.47
1 year 0.03
Extreme 0.028
0.47
3 years 0.03
Extreme 0.028
0.48
5 years 0.03
Extreme 0.028
0.71
10 years 0.03
Extreme 0.028
0.72
Manager TitleAgeSince
Chief Executive Officer 53 09/07/2014
Director of Finance/CFO - 01/03/2018
Chief Tech/Sci/R&D Officer - 01/07/2025
Director TitleAgeSince
Director/Board Member 53 09/07/2014
Chairman 76 17/11/2017
Director/Board Member 57 12/02/2014
Date Insider Type Main position Quantity % Market Cap.
03-18Other

Executive/Senior Manager

5,174,048 0.3511%
03-18Other

Chief Operating Officer

4,667,305 0.3167%
03-18Other

Chief Technology Officer

758,059 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-1.92%-8.93%-79.60%-83.55% 53.2M
+0.58%+2.06%+2.92%+10.86% 50.44B
-2.56%-2.02%+383.53%+584.16% 40.63B
-0.48%+1.03%+25.71%-5.17% 34.88B
-1.68%-3.90%+17.37%+54.47% 33.67B
+1.21%-0.79%+4.46%+35.18% 26.29B
-2.47%+0.28% - - 17.11B
-0.73%-5.60%+62.51%+120.61% 15.29B
-9.09%-29.62%+38.13%+40.11% 10.62B
+0.23%-0.58%+13.76%+21.11% 13.74B
Average -1.70%-2.62%+52.09%+86.42% 24.27B
Weighted average by Cap. -1.08%-0.03%+83.66%+130.39%

Financials

2026 *2027 *
Net sales 17.23M 11.96M 10.47M 9.65M 8.93M 16.95M 1.14B 116M 45.31M 561M 44.91M 43.94M 1.94B 3.15M 2.19M 1.91M 1.77M 1.63M 3.1M 209M 21.14M 8.29M 103M 8.21M 8.04M 355M
Net income -58.54M -40.64M -35.55M -32.79M -30.34M -57.58M -3.88B -393M -154M -1.91B -153M -149M -6.6B -47.05M -32.67M -28.58M -26.35M -24.38M -46.28M -3.12B -316M -124M -1.53B -123M -120M -5.3B
Net Debt -65.09M -45.19M -39.53M -36.45M -33.73M -64.02M -4.31B -437M -171M -2.12B -170M -166M -7.34B -77.26M -53.64M -46.92M -43.27M -40.04M -75.99M -5.12B -518M -203M -2.51B -201M -197M -8.71B
Logo Immutep Limited
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Employees
31
Date Price Change Volume
10/07/26 A$0.0510 -1.92% 2,692,312
09/07/26 A$0.0520 -1.89% 3,911,401
08/07/26 A$0.0530 -3.64% 7,019,166
07/07/26 A$0.0550 0.00% 19,487,912
06/07/26 A$0.0550 0.00% 2,914,012
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
0.0510AUD
Average target price
0.1033AUD
Spread / Average Target
+102.61%

Quarterly revenue - Rate of surprise